Literature DB >> 8699065

Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting.

B J Johnson1, K E Robbins, R E Bailey, B L Cao, S L Sviat, R B Craven, L W Mayer, D T Dennis.   

Abstract

An ELISA containing a purified flagellar antigen from Borrelia burgdorferi (FLA-ELISA) was evaluated. The FLA-ELISA, detecting IgM and IgG together, did not have adequate specificity by itself. Good accuracy was obtained, however, when the FLA-ELISA was the first step in a two-step protocol that used immunoblotting as a conditional second test. Samples that scored positive or equivocal by the FLA-ELISA were evaluated with separate IgM and IgG immunoblots. The sensitivity of the two-step process for patients with erythema migrans or with later manifestations of Lyme disease was 64% and 100%, respectively. The specificity for health blood donors was 100% and was 90% for the aggregate of all persons with illness that may cause serologic cross-reactivity (98% if the samples from relapsing fever patients were excluded). Test precision was 96% overall, 99% for Lyme disease case serum samples, 100% for specimens from blood donors, and 88% for samples from persons with other illness.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699065     DOI: 10.1093/infdis/174.2.346

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Effects of OspA vaccination on Lyme disease serologic testing.

Authors:  M E Aguero-Rosenfeld; J Roberge; C A Carbonaro; J Nowakowski; R B Nadelman; G P Wormser
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

2.  Identifying diagnostic peptides for lyme disease through epitope discovery.

Authors:  G A Kouzmitcheva; V A Petrenko; G P Smith
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

3.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 4.  Overdiagnosis and overtreatment of Lyme neuroborreliosis are preventable.

Authors:  A Prasad; D Sankar
Journal:  Postgrad Med J       Date:  1999-11       Impact factor: 2.401

5.  Two-year evaluation of Borrelia burgdorferi culture and supplemental tests for definitive diagnosis of Lyme disease.

Authors:  Peggy Coulter; Clara Lema; Diane Flayhart; Amy S Linhardt; John N Aucott; Paul G Auwaerter; J Stephen Dumler
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

6.  Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics.

Authors:  Richard B Porwancher; C Greg Hagerty; Jianqing Fan; Lisa Landsberg; Barbara J B Johnson; Mark Kopnitsky; Allen C Steere; Karen Kulas; Susan J Wong
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

7.  Recombinant chimeric Borrelia proteins for diagnosis of Lyme disease.

Authors:  M J Gomes-Solecki; J J Dunn; B J Luft; J Castillo; D E Dykhuizen; X Yang; J D Glass; R J Dattwyler
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

8.  Evaluation of whole-cell and OspC enzyme-linked immunosorbent assays for discrimination of early lyme borreliosis from OspA vaccination.

Authors:  C A Wieneke; S D Lovrich; S M Callister; D A Jobe; J A Marks; R F Schell
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

9.  FlaA, a putative flagellar outer sheath protein, is not an immunodominant antigen associated with Lyme disease.

Authors:  Y Ge; N W Charon
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

10.  Significant improvement of the recombinant Borrelia-specific immunoglobulin G immunoblot test by addition of VlsE and a DbpA homologue derived from Borrelia garinii for diagnosis of early neuroborreliosis.

Authors:  Ulrike Schulte-Spechtel; Gisela Lehnert; Gaby Liegl; Volker Fingerle; Christiane Heimerl; Barbara J B Johnson; Bettina Wilske
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.